Syros Pharmaceuticals, Inc. focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome.
Market Cap | 23.312 Million | Shares Outstanding | 6.301 Million | Avg 30-day Volume | 88.979 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -3.35 |
Price to Revenue | 6.0111 | Debt to Equity | 0.5722 | EBITDA | -89.588 Million |
Price to Book Value | 0.6964 | Operating Margin | -1151.7102 | Enterprise Value | -30.385 Million |
Current Ratio | 7.373 | EPS Growth | 0.783 | Quick Ratio | 7.115 |
1 Yr BETA | 0.9931 | 52-week High/Low | 11.5 / 2.42 | Profit Margin | -754.4028 |
Operating Cash Flow Growth | -20.8075 | Altman Z-Score | -4.07 | Free Cash Flow to Firm | -111.434 Million |
Earnings Report | 2023-08-09 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
12,000 | 2023-06-01 | 2 | |
|
29,189 | 2023-06-01 | 5 | |
|
0 | 2023-06-01 | 3 | |
|
12,000 | 2023-06-01 | 2 | |
|
0 | 2023-06-01 | 2 | |
|
36,171 | 2023-06-01 | 2 | |
|
0 | 2023-06-01 | 2 | |
|
12,000 | 2023-06-01 | 3 | |
|
12,000 | 2023-06-01 | 2 | |
SIMONIAN NANCY A PRESIDENT & CEO |
|
73,420 | 2023-03-31 | 3 |
ROTH DAVID CHIEF MEDICAL OFFICER |
|
7,348 | 2023-03-31 | 3 |
OLSON ERIC R CHIEF SCIENTIFIC OFFICER |
|
7,350 | 2023-03-31 | 3 |
STEPHENS KRISTIN CHIEF DEVELOPMENT OFFICER |
|
4,465 | 2023-03-31 | 3 |
CHEE CONLEY CHIEF COMMERCIAL OFFICER |
|
1,342 | 2023-03-31 | 4 |
HAAS JASON CHIEF FINANCIAL OFFICER |
|
1,377 | 2023-03-31 | 3 |
QUIRK GERALD E CHIEF LEGAL OFFICER |
|
45,000 | 2022-10-11 | 2 |
|
17,500 | 2022-06-01 | 0 | |
|
17,500 | 2022-06-01 | 0 | |
SPRINGHORN JEREMY P. CHIEF BUSINESS OFFICER |
|
0 | 2021-02-17 | 0 |
FERRA JOSEPH J JR CHIEF FINANCIAL OFFICER |
|
0 | 2021-02-17 | 0 |
ARCH VENTURE PARTNERS VII, L.P. |
|
No longer subject to file | 2019-07-15 | 0 |
|
0 | 2019-06-11 | 0 | |
|
0 | 2019-06-11 | 0 | |
|
0 | 2019-06-11 | 0 | |
|
0 | 2017-12-31 | 0 | |
DESIMONE COLLEEN ELIZABETH PRINCIPAL ACCOUNTING OFFICER |
|
0 | 2017-10-23 | 0 |
FLAGSHIP VENTURES FUND IV, L.P. FLAGSHIP VENTURES FUND IV-RX, L.P. |
|
3,253,491 | 2017-08-17 | 0 |
|
0 | 2017-06-08 | 0 | |
|
0 | 2017-06-08 | 0 | |
KUVALANKA KYLE D. CHIEF OPERATING OFFICER |
|
0 | 2017-02-10 | 0 |
|
0 | 2016-09-15 | 0 | |
|
2,095,220 | 2016-07-06 | 0 | |
AISLING CAPITAL PARTNERS III LP |
|
No longer subject to file | 2016-07-06 | 0 |
ARCH VENTURE PARTNERS VII, L.P. |
|
4,637,137 | 2016-07-06 | 0 |
|
No longer subject to file | 2016-07-06 | 0 | |
|
No longer subject to file | 2016-07-06 | 0 | |
|
No longer subject to file | 2016-07-06 | 0 | |
|
No longer subject to file | 2016-07-06 | 0 | |
|
426,666 | 2016-06-29 | 0 | |
CONDE JORGE CHIEF STRATEGY OFFICER |
|
0 | 2016-06-29 | 0 |
|
351,666 | 2016-06-29 | 0 | |
|
351,666 | 2016-06-29 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-06-02 16:22:24 -0400 | 2023-06-01 | A | 6,000 | a | 6,000 | direct | ||||||||||
2023-06-02 16:26:13 -0400 | 2023-06-01 | A | 6,000 | a | 6,000 | direct | ||||||||||
2023-06-02 16:26:13 -0400 | 2023-06-01 | A | 4,000 | a | 29,189 | direct | ||||||||||
2023-06-02 16:25:36 -0400 | 2023-06-01 | A | 6,000 | a | 6,000 | direct | ||||||||||
2023-06-02 16:25:36 -0400 | 2023-06-01 | A | 4,000 | a | 12,000 | direct | ||||||||||
2023-06-02 16:26:57 -0400 | 2023-06-01 | A | 6,000 | a | 6,000 | direct | ||||||||||
2023-06-02 16:26:57 -0400 | 2023-06-01 | A | 4,000 | a | 12,000 | direct | ||||||||||
2023-06-02 16:27:26 -0400 | 2023-06-01 | A | 6,000 | a | 6,000 | direct | ||||||||||
2023-06-02 16:27:26 -0400 | 2023-06-01 | A | 4,000 | a | 36,171 | direct | ||||||||||
2023-06-02 16:24:58 -0400 | 2023-06-01 | A | 4,000 | a | 12,000 | direct | ||||||||||
2023-06-02 16:22:24 -0400 | 2023-06-01 | A | 4,000 | a | 4,000 | direct | ||||||||||
2023-06-02 16:22:54 -0400 | 2023-06-01 | A | 6,000 | a | 6,000 | direct | ||||||||||
2023-06-02 16:22:54 -0400 | 2023-06-01 | A | 4,000 | a | 4,000 | direct | ||||||||||
2023-06-02 16:23:39 -0400 | 2023-06-01 | A | 6,000 | a | 6,000 | direct | ||||||||||
2023-06-02 16:23:39 -0400 | 2023-06-01 | A | 4,000 | a | 4,000 | direct | ||||||||||
2023-06-02 16:24:22 -0400 | 2023-06-01 | A | 6,000 | a | 6,000 | direct | ||||||||||
2023-06-02 16:24:22 -0400 | 2023-06-01 | A | 4,000 | a | 12,000 | direct | ||||||||||
2023-06-02 16:24:58 -0400 | 2023-06-01 | A | 6,000 | a | 6,000 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 22:15:03 UTC | -5.7385 | 10.8085 | 95000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 21:45:05 UTC | -5.7385 | 10.8085 | 95000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 21:15:04 UTC | -5.7385 | 10.8085 | 95000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 20:45:04 UTC | -5.7385 | 10.8085 | 95000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 20:15:04 UTC | -5.7385 | 10.8085 | 95000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 19:45:04 UTC | -5.7385 | 10.8085 | 95000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 19:15:03 UTC | -5.7385 | 10.8085 | 95000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 18:45:04 UTC | -5.7385 | 10.8085 | 95000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 18:15:04 UTC | -5.7385 | 10.8085 | 95000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 17:45:04 UTC | -5.7385 | 10.8085 | 95000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 17:15:04 UTC | -5.7385 | 10.8085 | 95000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 16:45:04 UTC | -5.7485 | 10.8085 | 95000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 16:15:03 UTC | -5.7485 | 10.8085 | 95000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 15:45:04 UTC | -5.7485 | 10.8085 | 95000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 15:15:04 UTC | -5.7485 | 10.8085 | 95000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 14:45:04 UTC | -7.3585 | 12.4185 | 95000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 14:15:03 UTC | -7.3585 | 12.4185 | 95000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 13:45:03 UTC | -7.3585 | 12.4185 | 90000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 13:15:03 UTC | -7.3585 | 12.4185 | 90000 |
SYROS PHARMACEUTICALS INC SYRS | 2023-06-06 12:45:05 UTC | -7.3585 | 12.4185 | 90000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|